Abstract
The main aim of the current research work is to evaluate the potential of lipid based solid dispersions (OSD) to enhance oral bioavailability of Olmesartan Medoxomil (BCS Class II molecule). OSD have been prepared using different hydrophilic lipid based carriers such as gelucire 44/14 and gelucire 50/13 at the ratio of 1: 1, 1: 2 and 1: 3. Pearlitol SD 200 was used as hydrophilic carrier in all the formulations to convert the lipid based solid dispersion to free flowing powder. Solid dispersions were prepared by solvent evaporation method. Prepared OSD's were evaluated for their micromeritics properties, saturation solubility, in vitro dissolution and ex vivo permeability. Among the formulations prepared, formulation (OSD3) containing gelucire 44/14 (1: 3), Pearlitol SD 200 as carrier has shown enhanced drug release (70.2 ± 6.5 release in 30 minutes) and solubility (44.32mg/mL) compared to other formulations. Hence, this formulation is evaluated for comparative ex vivo permeability with pure drug and marketed formulation (Olmezest). It was found that the permeability of OSD3 was increased compared to pure drug and compared to marketed formulation. Hence, the study demonstrated that lipid based solid dispersion technology can lead to improve the bioavailability of poorly soluble drugs like olmesartan medoxomil significantly.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
